Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled study of subcutaneous efgartigimod PH20 in adults with primary Sjögren's syndrome with open-label extension
CTR20252164Phase 3Active
- Sponsor
- argenx
- Start
- Aug 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa in primary Sjögren's syndrome, sponsored by argenx. Started Aug 2025; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on CTR20252164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252164.